One-prime multi-boost strategy immunization with recombinant DNA, adenovirus, and MVA vector vaccines expressing HPV16 L1 induces potent, sustained, and specific immune response in mice

Antiviral Research
Li-Li LiYi Zeng

Abstract

Human papillomavirus (HPV) is associated with various human diseases, including cancer, and developing vaccines is a cost-efficient strategy to prevent HPV-related disease. The major capsid protein L1, which an increasing number of studies have confirmed is typically expressed early in infection, is a promising antigen for such a vaccine, although the E6 and E7 proteins have been characterized more extensively. Thus, the L1 gene from HPV16 was inserted into a recombinant vector, AdHu5, and MVA viral vectors, and administered by prime-boost immunization. Virus-like particles were used as control antigens. Our results indicate that prime-boost immunization with heterologous vaccines induced robust and sustained cellular and humoral response specific to HPV16 L1. In particular, sera obtained from mice immunized with DNA + DNA + Ad + MVA had excellent antitumor activity in vivo. However, the data also confirm that virus-like particles can only elicit low levels cellular immunity and not be long-lasting, and are therefore unsuitable for treatment of existing HPV infections.

References

Feb 1, 1992·Human Pathology·M H StolerT R Broker
Apr 1, 1995·The Journal of Infectious Diseases·M EvanderG Wadell
Feb 5, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·A Reyes-Sandoval, H C J Ertl
May 12, 2004·Lancet·M L Gillison, D R Lowy
May 26, 2005·Virology·Mark SchiffmanRobert D Burk
Aug 21, 2007·JAMA : the Journal of the American Medical Association·Allan HildesheimUNKNOWN Costa Rican HPV Vaccine Trial Group
Sep 11, 2012·BMC Cancer·Margaret A StanleyPeter K C Goon
Dec 3, 2014·La Presse médicale·Silvia de SanjoséLaia Alemany
Dec 3, 2014·Oral Oncology·Wojciech K MydlarzJeremy D Richmon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.